3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
10
Lymphoma, Mantle-Cell
9
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Follicular
4
Lymphoma, B-Cell
4
Waldenstrom Macroglobulinemia
3
Recurrence
3
Lymphoma, B-Cell, Marginal Zone
3
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Neoplasms
1
Multiple Myeloma
1
Mature B-Cell Malignancies
1
Hematologic Diseases
1
Interventions
Dexamethasone
114
daratumumab
68
Lenalidomide
66
Bortezomib
55
pomalidomide
44
carfilzomib
39
Cyclophosphamide
33
Specimen Handling
30
Calcium Dobesilate
30
Biopsy
27
Magnetic Resonance Spectroscopy
24
belantamab mafodotin
20
isatuximab
19
fludarabine
17
talquetamab
16
iberdomide
15
Melphalan
15
dexamethasone acetate
13
dexamethasone 21-phosphate
13
auricularum
13
fludarabine phosphate
11
selinexor
10
elotuzumab
10
tocilizumab
9
X-Rays
8
Nivolumab
8
Sirolimus
7
trametinib
6
Whole-Body Irradiation
6
Mycophenolic Acid
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Multiple Myeloma
×
zanubrutinib
×
90 days
×
Clear all
NCT07474961
2026-03-16
BLOOD-dose
Rigshospitalet, Denmark
Phase 4
Not yet recruiting
400 enrolled